Inactive Instrument

Peloton Therapeutics, Inc.

Equities

PLTX

US70614L1044

Biotechnology & Medical Research

Peloton Therapeutics, Inc. announced that it has received $74.6 million in funding from Foresite Capital Management, LLC, Remeditex Ventures, LLC, The Column Group LLC, Topspin Partners LBO, LP, Nextech Invest Ltd., Tichenor Ventures, LLC

March 13, 2017

On March 14, 2017. Peloton Therapeutics, Inc. closed the transaction. The company received $22,200,000 in its second and final tranche of the transaction. The company has raised $74,600,000 in funding so far in the transaction.

Latest news about Peloton Therapeutics, Inc.

Merck & Co., Inc. completed the acquisition of Peloton Therapeutics, Inc. from The Column Group LLC.	19-07-29	CI
Peloton Therapeutics, Inc. has withdrawn its IPO in the amount of $159.375 million.	19-07-10	CI
Merck & Co., Inc. signed a definitive agreement to acquire Peloton Therapeutics, Inc. from The Column Group LLC for $2.2 billion.	19-05-20	CI
Peloton Therapeutics Announces Board Changes	19-05-14	CI
Peloton Therapeutics, Inc. has filed an IPO in the amount of $115 million.	19-04-26	CI
Peloton Therapeutics To Seek Acquisitions	19-04-26	CI
Peloton Therapeutics, Inc. announced that it has received $150 million in funding from a group of investors	19-02-19	CI
Peloton Therapeutics Announces Appointment of John Moore as General Counsel and Corporate Secretary	18-12-04	CI
Peloton Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer	18-08-14	CI
Peloton Therapeutics Initiates Phase 2 Trial of OralHIF-2a Inhibitor PT2977 for Treatment of Von Hippel-Lindau Disease-Associated Kidney Cancer	18-06-06	CI
Peloton Therapeutics, Inc. Announces Board Changes	18-03-22	CI
Peloton Therapeutics, Inc. Announces Results from A Phase 1 Study Evaluating PT2385 in Patients with Advanced Kidney Cancer	17-12-20	CI
Peloton Therapeutics, Inc. Initiates Patient Dosing in Phase 2 Study of PT2385 for Von Hippel-Lindau Disease-Associated Kidney Cancer	17-05-11	CI
Peloton Therapeutics, Inc. Appoints Mohammad Hirmand as Chief Medical Officer, Effective from May 1, 2017	17-04-03	CI
Peloton Therapeutics, Inc. announced that it has received $74.6 million in funding from Foresite Capital Management, LLC, Remeditex Ventures, LLC, The Column Group LLC, Topspin Partners LBO, LP, Nextech Invest Ltd., Tichenor Ventures, LLC	17-03-13	CI
Peloton Therapeutics, Inc. announced that it expects to receive $52.4 million in funding from Foresite Capital Management, LLC, Remeditex Ventures, LLC, The Column Group LLC, Topspin Partners LBO, LP, Nextech Invest Ltd., Tichenor Ventures, LLC	16-09-14	CI
Peloton Therapeutics, Inc. Presents Clinical Data on First-In-Class Oral HIF-2a Inhibitor in Patients with Advanced Kidney Cancer	16-06-06	CI
Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2a Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting	16-04-19	CI

Chart Peloton Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Peloton Therapeutics, Inc. is a clinical stage pharmaceutical company. The Company is focused on developing medicines for patients with cancer and other conditions. The Company's product pipeline includes Hypoxia-inducible factor-2? (HIF-2?). HIF-2? is a transcription factor that, in part, regulates the body's response to diminished availability of oxygen. The Company's lead drug candidate, PT2977, is an oral HIF-2?. The Company is focused on developing PT2977 for the treatment of kidney cancer, specifically metastatic clear cell renal cell carcinoma (mRCC) and von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC). HIF-2? is aberrantly activated in these diseases as a result of the inactivity of the VHL tumor suppressor. The Company is also developing PT2567, an oral HIF-2? inhibitor, for non-oncology indications.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.82%	127B
REGENERON PHARMACEUTICALS, INC.	+21.96%	116B
ARGENX SE	+23.87%	27.69B
BIONTECH SE	-22.97%	19.62B
GENMAB A/S	-16.89%	16.26B
BEIGENE, LTD.	-19.03%	15.49B
NEUROCRINE BIOSCIENCES, INC.	+11.66%	14.81B
WUXI APPTEC CO., LTD.	-48.41%	14.39B
SAREPTA THERAPEUTICS, INC.	+54.78%	14.11B

Bio Therapeutic Drugs